Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in crohn's disease

N. K.H. De Boer*, L. J.J. Derijks, J. J. Keizer-Garritsen, L. H.J. Lambooy, W. Ruitenbeek, P. M. Hooymans, A. A. Van Bodegraven, D. J. De Jong

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The proposed metabolic advantage of 6-thioguanine (6-TG) is the direct conversion into the pharmacologically active 6-thioguaninenucleotides (6-TGN). The authors assessed metabolic characteristics of 6-TG treatment in patients with Crohn's disease (N= 7) on therapy with 20 mg 6-TG. 6-thioguanine- monophosphate (6-TGMP), 6-thioguanine-diphosphate (6-TGDP), and 6-thioguanine-triphosphate (6-TGTP) were measured by high-performance liquid chromatography analysis in erythrocytes. Thiopurine S-methyltransferase activity and total 6-TGN levels were determined by standard methods. High interindividual variance in metabolite measurements was observed. Main metabolites were 6-TGTP (median = 531 pmol/8 × 108 red blood cells) and 6-TGDP (median = 199 pmol/8 × 108 red blood cells). Traces of 6-TGMP (median = 39 pmol/8 × 108 red blood cells) and 6-TG (2 patients) could be detected. 6-TGN levels correlated with 6-TGTP levels (r = 0.929, P =.003) and with the sum of separate nucleotides (r = 0.929, P =.003). No correlations were established between TPMT activity (median = 13 pmol/h/107) and 6-TG metabolites. The 1-step metabolism of 6-TG still leads to high interindividual variance in metabolite concentrations. Total 6-TGN level monitoring may suffice for clinical practice.

Original languageEnglish
Pages (from-to)187-191
Number of pages5
JournalJournal of Clinical Pharmacology
Volume47
Issue number2
DOIs
Publication statusPublished - 1 Feb 2007

Cite this

De Boer, N. K. H., Derijks, L. J. J., Keizer-Garritsen, J. J., Lambooy, L. H. J., Ruitenbeek, W., Hooymans, P. M., ... De Jong, D. J. (2007). Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in crohn's disease. Journal of Clinical Pharmacology, 47(2), 187-191. https://doi.org/10.1177/0091270006294403